retatrutide phase 2 trial obesity nejm 2023 Research Guide: What the Data Reported (2026) 🤔 Adults with type 2

This offers a more accessible treatment pathway for individuals who may have needle anxiety or prefer the convenience of oral medication

Eli Lilly has not publicly disclosed the commercial device format for retatrutide

But just two months later, in June, Novo Nordisk said its products would no longer be available through Hims & Hers, blasting the platform for endangering patients by failing to adhere to laws against mass compounding under the false guise of personalization, causing its stock to collapse 35% from $64.22 at market close on the last trading day to $41.98 the day of the announcement, based on historical data.

TRIUMPH-1, the first Phase 3 efficacy readout, was reported on 21 May 2026

The relative infant dose (RID), or the maternal weight-adjusted infant dose, was calculated, considering the bioavailability of semaglutide and long-acting dose profiles

Amycretin (Zenagamtide) This is Novo's next-generation molecule and potentially their most exciting one yet